Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity

[1]  S. McCormack,et al.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses , 2008, The Journal of experimental medicine.

[2]  R. Zinkernagel,et al.  Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors , 2008, The Journal of experimental medicine.

[3]  S. Kochanek,et al.  Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  R. Steinman.  Dendritic cells: versatile controllers of the immune system , 2007, Nature Medicine.

[5]  D. von Laer,et al.  Decreased tumor surveillance after adoptive T-cell therapy. , 2007, Cancer research.

[6]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[7]  G. Pantaleo,et al.  Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. , 2007, Vaccine.

[8]  X. de Lamballerie,et al.  Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France , 2007, Transfusion.

[9]  Arjun Srinivasan,et al.  Transmission of lymphocytic choriomeningitis virus by organ transplantation. , 2006, The New England journal of medicine.

[10]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[11]  F. Cosset,et al.  DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. , 2006, Vaccine.

[12]  A. Bergthaler,et al.  Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Krebs,et al.  Rapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus1 , 2005, The Journal of Immunology.

[14]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[15]  B. Berkhout,et al.  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.

[16]  R. Zinkernagel,et al.  Kinetics of protective antibodies are determined by the viral surface antigen. , 2004, The Journal of clinical investigation.

[17]  Michael Basler,et al.  Immunodominance of an Antiviral Cytotoxic T Cell Response Is Shaped by the Kinetics of Viral Protein Expression1 , 2003, The Journal of Immunology.

[18]  Ana B. Sánchez,et al.  Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. V. Saz,et al.  Lymphocytic choriomeningitis virus infection in a province of Spain: Analysis of sera from the general population and wild rodents , 2003, Journal of medical virology.

[20]  G. Kollias,et al.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. , 2003, Immunity.

[21]  R. Koup,et al.  Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses , 2003 .

[22]  Dirk Homann,et al.  Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory , 2001, Nature Medicine.

[23]  Hao Shen,et al.  Organ-Specific Regulation of the CD8 T Cell Response to Listeria monocytogenes Infection1 , 2001, The Journal of Immunology.

[24]  M. Buchmeier,et al.  Arenaviridae: The viruses and their replication , 2001 .

[25]  Andreas Holz,et al.  Immunosuppression and Resultant Viral Persistence by Specific Viral Targeting of Dendritic Cells , 2000, The Journal of experimental medicine.

[26]  Caiying Guo,et al.  Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon cre‐mediated excision , 2000, Genesis.

[27]  P. Romero,et al.  Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue , 2000, The Journal of Immunology.

[28]  J. Miller,et al.  CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Klenerman,et al.  Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Osterhaus,et al.  Low prevalence of antibodies against the zoonotic agents Brucella abortus, Leptospira spp., Streptococcus suis serotype II, hantavirus, and lymphocytic choriomeningitis virus among veterinarians and pig farmers in the southern part of The Netherlands. , 1999, The Veterinary quarterly.

[31]  H. Pircher,et al.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.

[32]  J. Yewdell,et al.  Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. , 1998, Journal of immunology.

[33]  R. Zinkernagel,et al.  Induction of Protective Cytotoxic T Cell Responses in the Presence of High Titers of  Virus-neutralizing Antibodies: Implications for Passive and Active Immunization , 1998, The Journal of experimental medicine.

[34]  Jeff F. Miller,et al.  Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell‐mediated immunity , 1997, Immunological reviews.

[35]  F. Lemonnier,et al.  HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice , 1997, The Journal of experimental medicine.

[36]  R. Zinkernagel,et al.  Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice , 1995, Journal of virology.

[37]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[38]  R. Lanford,et al.  Prevalence of serum antibodies against lymphocytic choriomeningitis virus in selected populations from two U.S. cities , 1992, Journal of medical virology.

[39]  H. Pircher,et al.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen , 1989, Nature.

[40]  R. Zinkernagel,et al.  Anti‐viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia‐recombinant virus expressing LCMV‐WE nucleoprotein or glycoprotein , 1989, European journal of immunology.